Welcome to our dedicated page for Cosciens Biopharma SEC filings (Ticker: CSCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing packed with clinical-trial data, FDA risk factors, and segment breakouts can feel overwhelming. Cosciens Biopharma’s documents are no exception: every 10-K, 10-Q, and 8-K hides crucial details about pipeline progress, proprietary extraction technology, and cosmetic ingredient revenue. That’s why this page starts where most investors struggle—with the questions you actually ask.
Want Cosciens Biopharma insider trading Form 4 transactions in real time? Need the Cosciens Biopharma quarterly earnings report 10-Q filing simplified? Stock Titan’s AI parses each disclosure the moment it hits EDGAR, producing plain-English summaries, red-flag alerts, and side-by-side comparisons. From Cosciens Biopharma Form 4 insider transactions real-time to the full text of every note, you get instant clarity instead of sifting through hundreds of pages.
Our coverage spans every form that matters:
- 10-K: See the Cosciens Biopharma annual report 10-K simplified with AI-highlighted R&D spending and clinical-stage milestones.
- 10-Q: Track quarter-over-quarter trial costs and revenue shifts with our Cosciens Biopharma earnings report filing analysis.
- 8-K: Get alerts on trial results or licensing deals via Cosciens Biopharma 8-K material events explained.
- Form 4: Monitor Cosciens Biopharma executive stock transactions Form 4 and gauge insider sentiment.
- Proxy (DEF 14A): Review the Cosciens Biopharma proxy statement executive compensation without wading through compensation tables.
Whether you're understanding Cosciens Biopharma SEC documents with AI for a deep-dive valuation or just checking a single item, our platform answers the natural questions analysts, portfolio managers, and clinicians ask every day. Cosciens Biopharma SEC filings explained simply — so you can focus on investment decisions, not document hunting.
COSCIENS Biopharma Inc. furnished a Form 6-K that includes its Q3 2025 interim financial materials and related certifications. The filing lists Exhibits 99.1–99.4, covering condensed interim consolidated financial statements for the third quarter of 2025, management’s discussion and analysis, and CEO/CFO certifications under National Instrument 52-109.
The exhibits are incorporated by reference into the company’s existing Form S-8 registration statements and are deemed part of those filings from the date this Form 6-K is furnished. The company also includes forward-looking statements and directs readers to risk factors in its most recent Annual Report on Form 20-F.
COSCIENS Biopharma Inc. furnished a Form 6-K noting it issued a press release with third quarter 2025 results and a strategic update, including a voluntary delisting from the Nasdaq Capital Market while maintaining its listing on the Toronto Stock Exchange.
The press release is attached as Exhibit 99.1 and is incorporated by reference into the company’s Registration Statements on Form S-8 (Nos. 333-224737, 333-210561, 333-200834, 333-279844). The filing reiterates forward-looking statement cautions and points investors to existing risk factors in its most recent Form 20-F and other filings.
FAQ
What is the current stock price of Cosciens Biopharma (CSCI)?
What is the market cap of Cosciens Biopharma (CSCI)?
